Status:
COMPLETED
Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19
Lead Sponsor:
Poitiers University Hospital
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The SARS-CoV-2 coronavirus pandemic is responsible for more than 180,000 deaths worldwide and 20,000 deaths in France. To date, no treatment or vaccine has been successful. Povidone-iodine is an antis...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adults (age over 18 yrs) of both sexes
- With positive SARS-CoV-2 carriage by RT-PCR
- Having given their written consent after having been informed
- Exclusion Criteria
- Patient with low viral load (threshold cycle \[Ct\] \> 25 per RT-PCR),
- Patient unable to perform oro-nasopharyngeal decolonization
- Known hypersensitivity to one of the constituents, particularly to povidone-iodine,
- History of dysthyroidism,
- Known coagulopathy,
- Participation in another clinical trial aimed at reducing viral load in patients with SARS-CoV-2,
- Pregnant or breastfeeding women, or women of childbearing age without effective contraception
- Patients not covered by a social security scheme
- Patients with enhanced protection
Exclusion
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 23 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04371965
Start Date
September 1 2020
End Date
October 23 2020
Last Update
October 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Poitiers
Poitiers, France, 86021